Lumibird SA

IPG Photonics Corporation shares jumped 14.4% after reporting second-quarter 2026 results that beat profit expectations and announcing a binding offer to acquire Lumibird Medical. Sales rose to US$278.58 million from US$250.72 million a year earlier, while net income eased to US$5.24 million from US$6.61 million and basic earnings per share from continuing operations moved to US$0.12 from US$0.16. The company highlighted ongoing 11% year-over-year revenue growth driven by industrial and emerging laser applications. The Lumibird Medical acquisition aims to broaden its medical laser platform and increase its potential medical market by about US$1 billion.

IPG Photonics reported second-quarter revenue of $279 million, an 11% increase from a year earlier and its third consecutive quarter of double-digit year-over-year sales growth. Industrial solutions revenue rose 16% year over year, led by battery-welding applications, while advanced solutions revenue declined 9% year over year but grew 10% sequentially on semiconductor demand tied to AI-related GPUs and high-bandwidth memory. The company agreed to acquire Lumibird Medical, a deal expected to expand its medical addressable market by about $1 billion and be accretive to gross margin, EBITDA, and adjusted earnings per share in its first year. Adjusted gross margin was 40.7%, adjusted diluted earnings per share were $0.58, and the company ended the quarter with $904 million in cash and investments and no debt. For the third quarter, IPG forecast revenue of $265 million to $295 million and adjusted diluted earnings per share of $0.30 to $0.60, including an estimated 150-basis-point tariff impact on adjusted gross margin.